We are live on
!
Find out more
VIA
Virtus Investment Advisers Portfolio holdings
AUM
$363M
1-Year Est. Return
34.89%
This Fund
S&P 500
This Quarter
Est. Return
-1.68%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$368M
AUM Growth
+$240M
(+188%)
Cap. Flow
+$255M
Cap. Flow
% of AUM
69.4%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
710
New
414
Increased
42
Reduced
13
Closed
237
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Virtus Newfleet ABS/MBS ETF
VABS
|
+$32.2M |
| 2 |
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
|
+$24.8M |
| 3 |
Virtus SEIX Senior Loan ETF
SEIX
|
+$19.2M |
| 4 |
SMC
Summit Midstream
SMC
|
+$4.35M |
| 5 |
OCCI
OFS Credit Co
OCCI
|
+$2.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICICI Bank
IBN
|
+$3.75M |
| 2 |
Virtus Duff & Phelps Clean Energy ETF
VCLN
|
+$2.74M |
| 3 |
Apple
AAPL
|
+$2.06M |
| 4 |
Microsoft
MSFT
|
+$2.02M |
| 5 |
Primoris Services
PRIM
|
+$1.86M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 24.48% |
| 2 | Healthcare | 11.95% |
| 3 | Technology | 8.6% |
| 4 | Industrials | 8.02% |
| 5 | Energy | 4.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Nurix Therapeutics
NRIX
$2.69B
| $94.9K | 0.03% |
+7,986
| New | +$134K |
|
|
AUTL
427
Autolus Therapeutics
AUTL
$551M
| $94.6K | 0.03% |
+61,027
| New | +$124K |
|
428
Arrowhead Research
ARWR
$12.5B
| $94.5K | 0.03% |
+7,415
| New | +$135K |
|
429
Olema Pharmaceuticals
OLMA
$1.04B
| $91.8K | 0.03% |
+24,427
| New | +$123K |
|
430
Keros Therapeutics
KROS
$212M
| $90.8K | 0.02% |
+8,907
| New | +$103K |
|
431
Relay Therapeutics
RLAY
$4.37B
| $90K | 0.02% |
+34,345
| New | +$135K |
|
432
Structure Therapeutics
GPCR
$3.82B
| $89.6K | 0.02% |
+5,177
| New | +$127K |
|
|
ATXS
433
DELISTED
Astria Therapeutics
ATXS
| $89.4K | 0.02% |
+16,735
| New | +$117K |
|
434
Stoke Therapeutics
STOK
$2.08B
| $88.6K | 0.02% |
+13,323
| New | +$124K |
|
435
Praxis Precision Medicines
PRAX
$10.2B
| $87.7K | 0.02% |
+2,316
| New | +$145K |
|
436
Vera Therapeutics
VERA
$2.27B
| $87.4K | 0.02% |
+3,637
| New | +$117K |
|
437
Rocket Pharmaceuticals
RCKT
$397M
| $87.1K | 0.02% |
+13,058
| New | +$129K |
|
|
RAPP
438
Rapport Therapeutics
RAPP
$2.25B
| $86.6K | 0.02% |
+8,637
| New | +$112K |
|
439
Neurogene
NGNE
$729M
| $86.1K | 0.02% |
+7,351
| New | +$128K |
|
440
Intellia Therapeutics
NTLA
$1.68B
| $86K | 0.02% |
+12,101
| New | +$122K |
|
441
Erasca
ERAS
$6.29B
| $85.5K | 0.02% |
+62,421
| New | +$107K |
|
442
Immunome
IMNM
$2.91B
| $84.5K | 0.02% |
+12,561
| New | +$121K |
|
443
Zentalis Pharmaceuticals
ZNTL
$297M
| $83.4K | 0.02% |
+52,449
| New | +$113K |
|
444
Viking Therapeutics
VKTX
$4.02B
| $82.8K | 0.02% |
+3,430
| New | +$108K |
|
445
Entrada Therapeutics
TRDA
$271M
| $81.9K | 0.02% |
+9,065
| New | +$113K |
|
446
Tango Therapeutics
TNGX
$4.51B
| $78.9K | 0.02% |
+57,599
| New | +$141K |
|
447
4D Molecular Therapeutics
FDMT
$582M
| $77.1K | 0.02% |
+23,864
| New | +$112K |
|
448
Arcus Biosciences
RCUS
$3.66B
| $75.1K | 0.02% |
+9,572
| New | +$111K |
|
449
Janux Therapeutics
JANX
$1B
| $72K | 0.02% |
+2,668
| New | +$101K |
|
450
Vaxcyte
PCVX
$8.67B
| $70.7K | 0.02% |
+1,872
| New | +$150K |
|
Similar funds
WI
MS
HS
SIAG
WTFG
A6
ACM
RGC
Virtus Investment Advisers's Q1 2025 Portfolio in Review
As of Q1 2025, Virtus Investment Advisers held 710 positions worth $368M, up 188% from $128M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Virtus Investment Advisers deployed $255M of net new capital in Q1 2025, opening 414 new positions and adding to 42 existing holdings. Its largest new stake was Virtus Newfleet ABS/MBS ETF: 1,321,000 shares worth $32.2M.
By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 16% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Berry Corp, an estimated $666K trimmed.
- Virtus Investment Advisers's largest Q1 2025 buy was Virtus Newfleet ABS/MBS ETF: 1,321,000 shares worth $32.2M.
- Virtus Investment Advisers added most to Yum China in Q1 2025, an estimated $1.42M increase.
- Virtus Investment Advisers's biggest Q1 2025 reduction was Berry Corp, cutting an estimated $666K.
- Virtus Investment Advisers fully exited ICICI Bank in Q1 2025, selling an estimated $3.75M.
- Virtus Investment Advisers's ten largest holdings make up 25% of its $368M portfolio in Q1 2025.
- Virtus Investment Advisers opened 414 new positions and closed 237 in Q1 2025.
- Virtus Investment Advisers's portfolio value rose 188% quarter-over-quarter to $368M.
Based on Virtus Investment Advisers's 13F filing for Q1 2025, filed 15 May 2025.